Oxford Immunotec – Proprietary tests for immune-regulated conditions
Perkin Elmer acquired Oxford Immunotec
Oxford Immunotec focused on developing and commercialising proprietary tests for immune-regulated conditions. On 2013 Oxford immunotec went public on NASDAQ via an IPO.
Industry
Diagnostics
Case facts
Location
United Kingdom
Status
Exit January 2021
